a well-demarcated mass attached to the aortic arch wall and obstructing the brachiocephalic trunk ostium (Figure 1 A-B) . There was no amplification of the contrast in the perfusion image of MRI, thus indicating the thrombus (Figure 1 A) .
The patient received intravenous unfractionated heparin followed by vitamin K antagonist (VKA) administration with a target international normalized ratio of 2-3 that resulted in a slight reduction in thrombus size within the first 3 weeks of therapy. At 12 months transoesophageal echocardiography, however, did not show any pathology in the aortic arch.
Given the data showing altered fibrin clot properties in patients with venous thromboembolism [6] and ischemic stroke [7] , we performed plasma fibrin structure/function analysis [6] , which demonstrated markedly altered fibrin clot characteristics, including reduced clot permeability (a marker of pore size, Ks) and compaction (a marker of clot stiffness) combined with faster clot formation (shorter lag phase of fibrin formation) and impaired clot lysis (prolonged lysis time and slower rate of D-dimer release from clots) as compared to values obtained for anticoagulated patients with distal deep vein thrombosis (Table I) .
Traditional cardiovascular risk factors explain arterial thrombosis in older patients [1] , especially after interventions [8] . In young patients without cardiac risk factors, mostly arterial thrombotic events occurred related to atrial fibrillation or factor V Leiden. Thrombophilia screening fails to identify predisposing factors in 30% to 50% of idiopathic thrombosis patients [3] . A new risk factor for prothrombotic events revealed in venous thromboembolism, altered fibrin clot properties, is rarely described in patients with arterial thrombosis [3] .
This study is the first to demonstrate AAT in a man with altered clot properties and reduced susceptibility to lysis. In the search for any cause of AAT in the patient with negative thrombophilia screening, abnormal features of plasma fibrin clot structure/function were detected. The propensity to faster formation of compact fibrin clots is associated with resistance to fibrinolysis, as evidenced by longer lysis time and lower lysis rate (Table I) . By analogy to cryptogenic venous thrombosis [6] or stroke [7] , such properties could also explain the occurrence of unexplained arterial thrombosis. Moreover, altered fibrin clot structure/function may be associated with an unusual location of thrombus formation. Mechanisms underlying the fibrin clot characteristics in the current patient remain unclear and most likely combine environmental as well as genetic factors [3] . Although a positive familial history of AAT suggests a genetic background, we cannot definitely rule out in our patient other factors such as inflammatory, lipoprotein (a) (not measured in the present study) [9] , or the effect of platelets and blood cells. An influence of other as yet unidentified genetic factors is also suggested.
It is unknown whether prolonged heparin administration, thrombolysis, high-intensity anticoagulant or a surgical excision is the best therapeutic option in such cases. Our study supports VKA therapy in AAT as shown in previous reports [3] . This approach is likely to prevent thrombus recurrence and its embolic complications. Our patient was also successfully treated with VKA since low thrombin activity during stable anticoagulation facilitates clot lysis.
In conclusion, the current report suggests that unfavorable fibrin clot features predispose to unexplained arterial thrombosis and embolism in young patients without thrombophilic factors, thus representing potential novel risk factors for thrombosis at untypical locations.
